Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

Samankaltaisia teoksia

• Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
  Tekijä: Tan, Shuguang, et al.
  Julkaistu: (2017)
• Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
  Tekijä: Tan, Shuguang, et al.
  Julkaistu: (2016)
• The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
  Tekijä: Chen, Danqing, et al.
  Julkaistu: (2019)
• Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
  Tekijä: Liu, Hongchuan, et al.
  Julkaistu: (2019)
• N‐glycosylation of PD‐1 promotes binding of camrelizumab
  Tekijä: Liu, Kefang, et al.
  Julkaistu: (2020)